课题基金 / 基金详情

Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core

Immune Responses to Malaria and HIV Infection and Immunization - Clinical Core
对疟疾和艾滋病毒感染的免疫反应和免疫接种 - 临床核心
批准号:
10198679
负责人:
Margaret Juliana McElrath
金额:
$16.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-19 至 2022-06-30

项目摘要

项目成果

Margaret Juliana McElrath的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Clinical Core, based within the Vaccine and Infectious Disease Division (VIDD) at Fred Hutchinson Cancer Research Center (FHCRC), will provide relevant expertise in clinical medicine, human subjects research, vaccine trials, and human immunology in support of the scientific aims of the Collaboration focused on the prevention and control of malaria and HIV. In order to most efficiently support the diverse aims of Collaboration projects, the CC will utilize a variety of resources including: 1) archived samples (e.g., cryopreserved PBMC, serum, plasma) from study participants in relevant completed or ongoing clinical trials, which comprise the primary source of clinical samples for Collaboration projects; 2) newly obtained samples from existing clinical natural history and control cohorts and from specifically designed sub-studies to enable more comprehensive analysis within ongoing or planned vaccine or treatment trials; and 3) samples acquired through the clinical expertise of collaborating clinicians accomplished in the safe sampling of specialized immunological reservoirs (e.g., bone marrow; lymph nodes; mucosa) using minimally invasive procedures in human volunteers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data